Keymed Biosciences Inc 02162
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 02162 is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- HKD 34.10
- Day Range
- HKD 33.50–35.35
- 52-Week Range
- HKD 26.60–64.80
- Bid/Ask
- HKD 34.30 / HKD 34.45
- Market Cap
- HKD 9.49 Bil
- Volume/Avg
- 378,500 / 1.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 22.75
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.39%
Company Profile
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 897
- Website
- https://www.keymedbio.com
Comparables
Valuation
|
Metric
|
02162
|
02257
|
02171
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.02 | 3.41 | 2.02 |
Price/Sales | 22.75 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
02162
|
02257
|
02171
|
|---|---|---|---|
Quick Ratio | 8.82 | 3.44 | 9.49 |
Current Ratio | 9.36 | 4.51 | 9.55 |
Interest Coverage | −24.76 | −86.17 | −174.85 |
Quick Ratio
02162
02257
02171
Profitability
|
Metric
|
02162
|
02257
|
02171
|
|---|---|---|---|
Return on Assets (Normalized) | −8.02% | −60.85% | −28.70% |
Return on Equity (Normalized) | −10.29% | −108.56% | −35.29% |
Return on Invested Capital (Normalized) | −11.03% | −94.28% | −35.38% |
Return on Assets
02162
02257
02171
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dqlsmynkx | Pzntn | $599.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ygkwszcd | Swnkjq | $117.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hgghzsgz | Fysjn | $108.5 Bil | |
MRNA
| Moderna Inc | Wdxtkxkz | Qspf | $63.9 Bil | |
BNTX
| BioNTech SE ADR | Kcynlmxd | Zjb | $23.4 Bil | |
ARGX
| argenx SE ADR | Xcpflgqk | Yqfgj | $21.7 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kfgykqx | Dwpgy | $18.7 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qdswqmygj | Gtwkls | $14.3 Bil | |
INCY
| Incyte Corp | Fzxqpsgb | Xlsdqsk | $12.9 Bil | |
UTHR
| United Therapeutics Corp | Vnzdpvp | Qgt | $12.1 Bil |